Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

52.55 +0.30 (+0.56%)

Delayed Quote Updated: 2:09 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

38 39 Next >

2 Small-Cap Growth Stocks With Room To Run ↗

April 24, 2024

These two small-cap growth stocks could be ready to run.

Via The Motley Fool

FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer

April 18, 2024

From Genentech

Via Business Wire

Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS

April 17, 2024

From Genentech

Via Business Wire

Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients ↗

April 15, 2024

Roche study results show prolonged survival in R/R diffuse large B-cell lymphoma patients treated with Columvi (glofitamab) + GemOx vs. Rituxan + GemOx.

Via Benzinga

Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study

April 15, 2024

From Genentech

Via Business Wire

Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%. ↗

April 14, 2024

Think globally with this high-yielding ETF.

Via The Motley Fool

Topics ETFs

Why Roche Holdings Stock Popped Today ↗

April 11, 2024

Roche's new Alzheimer's test has a long road ahead of it, but it may help boost the pharmaceutical company's slow growth rate.

Via The Motley Fool

Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take. ↗

April 10, 2024

Recursion is playing the long game with its AI-focused approach to drug discovery and development.

Via The Motley Fool

Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data ↗

April 08, 2024

The latest findings from Alnylam Pharmaceuticals' KARDIA-2 Phase 2 study are on zilebesiran's efficacy and safety in treating hypertension. Results show significant reductions in systolic blood...

Via Benzinga

Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst ↗

April 08, 2024

Sarepta stock has taken a beating this year, and it might not be over with the first-quarter report looming.

Via Investor's Business Daily

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback ↗

March 28, 2024

The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.

Via Investor's Business Daily

Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs ↗

March 22, 2024

The market for weight loss drug stocks is massive, and these three companies could be the biggest beneficiaries of this trend.

Via InvestorPlace

Why Is European Pharma Giant Argenx Valued At Over $20B Trading Higher On Thursday? ↗

March 21, 2024

Argenx shares rise on Chugai's gMG trial disappointment. FDA-approved Vyvgart for anti-acetylcholine receptor antibody-positive adult patients. Enspryng's Phase 3 study results disappoint. Vyvgart...

Via Benzinga

Swiss Healthcare Manufacturing Firm Lonza Bolsters Biologics Manufacturing Capacity With Roche's US Facility Acquisition For $1.2B ↗

March 20, 2024

Lonza expands biologics manufacturing capacity with acquisition of Genentech facility in Vacaville, CA. $1.2 billion deal includes employee retention and facility upgrades. Transaction expected to...

Via Benzinga

FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer ↗

March 15, 2024

FDA approves BeiGene's Tevimbra for esophageal squamous cell carcinoma, offering hope for patients after prior chemotherapy. Tevimbra's efficacy was demonstrated in the RATIONALE 302 trial with...

Via Benzinga

Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach' ↗

March 11, 2024

Goldman Sachs urges investors to diversify geographically due to high concentration in US tech stocks, with Japan, healthcare, and European GRANOLAS highlighted as promising markets.

Via Benzinga

Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates ↗

March 09, 2024

This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung...

Via Talk Markets

FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer ↗

March 08, 2024

FDA grants accelerated approval to BeiGene's Brukinsa for relapsed/refractory follicular lymphoma. Approved in combination with Roche's Gazyva after two or more lines of therapy. Brukinsa, priced at...

Via Benzinga

Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial, Analyst Says Zilebesiran As Promising Opportunity In Addressing Global Hypertension Challenges ↗

March 05, 2024

Alnylam's KARDIA-2 Phase 2 study on zilebesiran, an RNAi therapeutic for hypertension. Clinically significant reductions in blood pressure observed, with optimistic outlook on upcoming ACC event.

Via Benzinga

11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields ↗

February 28, 2024

A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year.

Via Benzinga

Celldex Stock Hits 11-Month High, Up 19%, On A Promising New Hives Treatment ↗

February 26, 2024

The company tested its treatment in chronic spontaneous urticaria. Almost 38% of patients had "complete control" after 12 weeks.

Via Investor's Business Daily

This Drug By Roche And Novartis Reduces Allergic Reactions Across Multiple Foods For People With Food Allergies ↗

February 26, 2024

Results from Roche's Phase 3 OUtMATCH study on Xolair for multi-food allergies. Published in NEJM, the study reveals increased tolerance in patients aged 1-55. FDA-approved expanded use for...

Via Benzinga

New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies

February 25, 2024

From Genentech

Via Business Wire

Move Over Magnificent 7, Say Hello to the GRANOLAS ↗

February 22, 2024

Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods.

Via InvestorPlace

FDA Fast-Tracks Review Of Sarepta's Groundbreaking Muscular Dystrophy Treatment With $1B Market In Sight ↗

February 16, 2024

Sarepta's Elevidys efficacy supplement accepted for Duchenne muscular dystrophy treatment expansion, potential $1 billion yearly opportunity. FDA review goal: June 21, 2024.

Via Benzinga

FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies

February 16, 2024

From Genentech

Via Business Wire

Monte Rosa Therapeutics' AI And Machine Learning Platform Is Adding Significant Value Creation in Cancer Research: Analyst ↗

February 15, 2024

Wedbush initiates coverage on Monte Rosa Therapeutics. With differentiated lead programs and AI-driven QuEEN platform, the company shows strong potential for value creation.

Via Benzinga

Topics Artificial Intelligence

Roche Terminates Cancer Drug Pact With Repare Therapeutics, Its Second Walkout Within A Month ↗

February 13, 2024

Repare Therapeutics regains global rights to camonsertib (RP-3500) after terminating collaboration with Roche. $40M milestone achieved.

Via Benzinga

New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)

February 01, 2024

From Genentech

Via Business Wire

Roche Walks Away From HOOKIPA Pharma-Partnered KRAS-Focused Cancer Deal ↗

January 29, 2024

HOOKIPA Pharma's strategic focus on HB-200 program for HPV16+ HNSCC, infectious disease cure collaboration with Gilead, and recent developments.

Via Benzinga

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.